Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN

Fig. 1

Adjusted means for the association between baseline anti-CarbV/anti-MCV antibodies and CFB in SDAI response. a Anti-CarbV (IgA). b Anti-CarbV (IgG). c Anti-CarbV (IgM). d Anti-MCV (IgA). e Anti-MCV (IgG). f Anti-MCV (IgM). Adjusted ORs for baseline antibodies were converted into corresponding adjusted probabilities of SDAI as a function of baseline antibody serum concentrations. Adjusted overall SDAI means as a function of serum baseline antibody concentrations were estimated using multivariable MMRM with continuous covariates fixed at their mean values and categorical covariates fixed at their proportional distribution in the data. Overall SDAI response was estimated from MMRM, averaging SDAI responses at all post-baseline visits (weeks 4, 12, 16, 20, 24, 32, 40, and 52). p values < 0.05 were considered statistically significant. a A statistically significant nonlinear association was found for anti-CarbV (IgA). Patients with higher baseline anti-CarbV (IgA) values were more likely to show an overall improvement in SDAI response (p = 0.002). b A significant linear association was found for anti-CarbV (IgG) (p = 0.033). c A significant baseline anti-CarbV (IgM)-by-treatment interaction was found (p < 0.001). The association between anti-CarbV (IgM) and SDAI depends on the treatment received at baseline. Patients randomized to MTX who had higher baseline anti-CarbV (IgM) were more likely to show lower overall SDAI improvement (p = 0.0021). An opposite association was observed for patients randomized to baricitinib; however, neither association was statistically significant (baricitinib, p = 0.0874; baricitinib + MTX, p = 0.0636). d, e No statistically significant association for anti-MCV (IgA) [p = 0.323] or IgG [p = 0.503] was observed. f A statistically significant nonlinear association was found for anti-MCV (IgM) (p = 0.036). BARI, baricitinib; CarbV, carbamylated vimentin; CFB, change from baseline; Ig, immunoglobulin; MCV, mutated citrullinated vimentin; mLOCF, modified last observation carried forward; MMRM, mixed model for repeated measures; MTX, methotrexate; ORs, odds ratios; SDAI, Simplified Disease Activity Index

Back to article page
\